OncoMatch/Clinical Trials/NCT07180927

DLL3 CAR-T Therapy Targeting Brain Tumors

Is NCT07180927 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies 4SCAR DLL3 T cells for glioblastoma of cerebellum.

Phase 1/2RecruitingShenzhen Geno-Immune Medical InstituteNCT07180927Data as of May 2026

Treatment: 4SCAR DLL3 T cells — The purpose of this study is to assess the feasibility, safety and efficacy of Delta-like ligand 3 (DLL3)-specific CAR-T cell therapy in patients with DLL3 positive brain tumors including glioblastomas and diffused intrinsic pontine or midline gliomas (DIPG or DMG). Another goal of the study is to learn more about the function of the anti-DLL3 CAR-T cells and their persistency in patients.

Check if I qualify

Extracted eligibility criteria

Cancer type

Glioblastoma

Prior therapy

Must have received: standard care of medication, such as gross total resection with concurrent radio-chemotherapy (~54 - 60 Gy, TMZ) (temozolomide)

Patients have received standard care of medication, such as gross total resection with concurrent radio-chemotherapy (~54 - 60 Gy, TMZ)

Cannot have received: gliadel implantation

Exception: within 4 weeks before study start

a prior history of gliadel implantation 4 weeks before this study start

Cannot have received: antibody based therapies

Exception: currently receiving

currently receiving antibody based therapies

Lab requirements

Blood counts

absolute neutrophile count ≥ 1500/mm^3; hemoglobin > 10 g/dL; platelets > 100000 /mm^3; peripheral blood absolute lymphocyte count must be above 0.8×10^9/L

Kidney function

creatinine < 1.5×ULN

Liver function

Bilirubin < 1.5×ULN; ALT or AST < 2.5×ULN

Cardiac function

satisfactory heart functions

satisfactory bone marrow, liver and kidney functions as defined by the following: absolute neutrophile count ≥ 1500/mm^3; hemoglobin > 10 g/dL; platelets > 100000 /mm^3; Bilirubin < 1.5×ULN; alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 2.5×ULN; creatinine < 1.5×ULN; peripheral blood absolute lymphocyte count must be above 0.8×10^9/L; satisfactory heart functions

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify